Hemispherx shares boost on FDA Ampligen study hope
This article was originally published in Scrip
Shares in the US biotech company Hemispherx BioPharma jumped by more than 30% on news that the FDA had agreed to accept for review new analyses of data from the company's AMP-516 Phase III trial of its investigational treatment for chronic fatigue syndrome, Ampligen. The company's NASDAQ-quoted stock rose 6 cents to $0.34 on 11 July, valuing the company at $44.9 million.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.